50 results about "Lower respiratory tract infection" patented technology

The present invention provides methods for preventing, managing, treating and / or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and / or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and / or LRI), and / or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and / or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and / or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2×105 M−1s−1 and a dissociation rate (koff) of less than 5×10−4 s−1.

The present invention provides methods for managing, treating and / or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and / or lower respiratory tract infection (LRI)), and / or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and / or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and / or wheezing and / or COPD in said patient.

The invention provides a cefuroxime sodium compound and a new preparation method thereof. The method comprises the following steps: performing acid-base reaction, absorbing with activated carbon, and separating and purifying with a chromatographic column. By adopting the method, the purity and content of cefuroxime sodium can be greatly increased, the product quality of the preparation can be increased, the toxic or side effects can be reduced and the safety of the preparations of the medicines for curing respiratory tract infection and urinary tract infection can be ensured; and compared with the prior art, the method has the advantages of simple and practical technology, mild reaction conditions, low cost, high yield and high product purity and is suitable for industrial production.

The invention provides a medicament for treating infectious diseases, a preparation method and the application thereof. The medicament is prepared from scutellaria baicalensis, jasmine, erigeron breviscapus and cholic acid, and has the following effects: by aiming at the central link--inflammatory reaction of an infectious disease, removing harmful substances such as inflammatory mediators, free radicals and the like, and improving the local microcirculation state, thereby alleviating the pathological damages caused by inflammations; meanwhile, the medicament has the function of regulating the overall internal environment, and can effectively treat lower respiratory tract infection and acute lung injury induced by infection; and the effective substances and functional mechanism of the medicament are relatively clear.

The invention discloses a medical mask special for enriching and sampling respiratory tract transmission pathogens. The medical mask comprises a main body protective layer, a resin nose bridge strip and ear bands, the main body protective layer is sequentially provided with a non-woven fabric protective layer, a melt-blown fabric filter layer, a non-woven fabric isolation layer, a melt-blown fabric pathogen enrichment layer and a non-woven fabric skin care layer from outside to inside, and cutting lines are arranged on the melt-blown fabric pathogen enrichment layer and the non-woven fabric skin care layer. According to the sampling mask, five-layer design is adopted, the outer three layers are used for filtering external dust and pathogens, and cross contamination of the external pathogens to the inner layer is avoided; the melt-blown cloth pathogen enrichment layer can enrich pathogens through continuous expiration of a sampled person, the detection sensitivity can be greatly improved, and the device is particularly suitable for lower respiratory tract infection pathogen sampling, such as a novel coronavirus pneumonia patient. The mask is worn by a sampled person, so that the infection risk of medical staff is greatly reduced. The method is simple in process, low in manufacturing cost, convenient to use, excellent in effect and good in popularization and application value.

The use of leukotrienes and other products of the 5-lipoxygenase pathway to enhance bacterial defense and treat infections is described. The products are especially useful when administered to the lungs for the treatment of pneumonia and other lower respiratory tract infections. The products may be administered for treatment or prophylactic purposes and may be administered concomitantly with antibiotics to combat infection.

The present invention provides methods for managing, treating and / or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and / or lower respiratory tract infection (LRI)), and / or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and / or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and / or wheezing and / or COPD in said patient.

The invention discloses an injection containing a pidotimod potassium salt and a preparation method thereof. The preparation method comprises the following steps of: undergoing reaction between pidotimod and potassium hydroxide with equal mole in water or other solvent or a mixed solution of multiple solvents, preparing the pidotimod potassium salt and then preparing the injection. The injection containing the pidotimod potassium salt is characterized in that the effective component, the pidotimod, in the injection exists in the form of the pidotimod potassium salt, thus the solubility and the stability of the pidotimod in normal pH environment of a human body are improved. The injection containing the pidotimod potassium salt, disclosed by the invention, is used for treating the recurrent upper and lower respiratory tract infection (such as pharyngitis, tracheitis, bronchitis and tonsillitis), the recurrent infection (such as rhinitis, nasosinusitis and otitis), the urinary infection and gynecological infection, and can reduce the times of acute exacerbation, shorten the course of disease and relieve the degree of exacerbation; in addition, the injection can be also taken as the auxiliary treatment of antibiotics during the acute infection.

The present invention discloses an oral solid preparation containing ambroxal hydrochloride and guaifenesin active components. It is made up by using ambroxol hydrochloride and guaifenesin as active components and auxiliary material according to a certain ratio through a certain preparation process. Said oral solid preparation can be used for mainly curing the diseases of chronic bronchitis and periodic lower respiratory tract infection.

The invention belongs to the novel technology field of the medicines and relates to a preparation and use of a ceftibuten dry suspension. The ceftibuten dry suspension is characterized by comprising, but not being limited by following excipients available by pharmacy: sucrose, mannitol, etc. as the loading agent; sodium chloride, aspartame, strawberry essence, etc. as the flavoring agent; carbomer, sodium carboxymethyl cellulose, sodium carboxy nethyl, etc. as the suspending agent. The ceftibuten dry suspension is used for treating: upper respiratory tract infection such as pharyngitis, antiaditis, scarlet fever, paranasal sinusitis, and otitis medium; lower respiratory tract infection such as acute bronchitis, acute attack of chronic bronchitis and pneumonia; urinary tract infection; enteritis and gastroenteritis.

The invention belongs to the novel technical field of medicaments, and relates to a novel dosage form of ceftibuten for treating upper respiratory tract infections, such as pharyngitis, tonsillitis, scarlatina, parasinusitis and tympanitis; lower respiratory tract infections, such as acute bronchitis, acute onset of chronic bronchitis, pneumonia; urinary tract infection; enteritis and gastroenteritis. The novel dosage form is characterized in that the product is a sustained release capsule which slowly releases drugs in the water or prescribed release media at non-constant speed. Through the slow release, the drugs reach a stable blood concentration level in vivo, and the undesirable reactions and drug-resistant strains thereof are reduced.

The invention provides a medicament for treating lower respiratory tract infection and a preparation method thereof, aiming at solving problems of poor effect on some pathogenic bacteria, difficult control of non-bacterial infection, high price and the like for preventing lower respiratory tract infection by using cephalosporin antibiotics in the prior art; the medicament comprises the following components by weight: 10-30 parts of fritillaria thun-bergli, 20-40 parts of almond, 10-15 parts of loquat leaves, 15-30 parts of white mulberry root bark, 6-10 parts of radix stemonae, 10-30 parts of rhizoma phragmitis, 10-15 parts of radix bupleuri, 6-10 parts of pinellia ternate, 10-15 parts of scutellaria, 30-60 parts of radix astragali, 10-15 parts of platycodon grandiflorum, 30-60 parts of gypsum, 10-15 parts of radix ophiopogonis, 20-40 parts of licorice, and 10-15 parts of citrus peel. The medicament of the invention adopts Chinese herbal medicine as main components, and has the advantages of no drug tolerance, easy control of non-bacterial infection, and low cost.

The present invention provides methods for preventing, managing, treating and / or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and / or lower respiratory tract infection (LRI)), and / or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a human subject, comprising topically administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and / or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and / or wheezing and / or COPD in said patient.

The invention relates to an anti-infection oral medicinal preparation and discloses a cefprozil medicinal composition. The cefprozil medicinal composition comprises cefprozil serving as an active ingredient, at least one filling agent, at least one disintegrating agent, at least one lubricating agent, 1 to 10 weight percent of pregelatinized starch and 0.5 to 2 weight percent of hydroxypropyl methylcellulose. The invention also relates to a preparation method for the preparation and application of the preparation to treatment for upper respiratory tract infection, lower respiratory tract infection and skin and skin soft tissue infection.

The invention relates to a medicament for treating cold by an enema method. The medicament for treating the cold by the enema method is prepared from the following raw materials by weight: 3 to 30 g of gypsum, 3 to 13 g of honeysuckle, 1 to 10 g of scrophularia niggpoensis, 2 to 15 g of rehmannia, 3 to 10 g of fructus forsythiae, 0.3 to 6 g of cape jasmine, 3 to 15 g of viola patrinii, 0.5 to 9 g of scutellaria baicalensis, 1 to 13 g of isatis root, 0.2 to 9 g of rhizoma anemarrhenae, 0.3 to 9 g of radix ophiopogonis and 1 to 6 mg of chlortrimeton. The medicament for treating the cold by the enema method has the advantages of dispelling wind, relieving exterior syndrome, releasing toxin, clearing heat, promoting production of body fluid, nourishing yin, resisting allergy, diminishing inflammation and relieving a cough. The formula of the medicament is mainly used for treating cold, influenza, upper and lower respiratory tract infection, and all kinds of febrile diseases.

The invention belongs to the technical field of medicaments, a chewable tablet of ceftibuten is used for treating upper respiratory tract infections, such as pharyngitis, tonsillitis, scarlatina, parasinusitis and tympanitis; lower respiratory tract infections, such as acute bronchitis, acute onset of chronic bronchitis and pneumonia; urinary tract infection; enteritis and gastroenteritis. The novel dosage form is characterized in that the product is a chewable tablet chewed or sucked in the mouth to dissolve for administration, and to take effect in the gastrointestinal tract or in the whole body through the absorption of the gastrointestinal tract.

The invention belongs to the novel technical field of medicaments, and relates to a novel dosage form of amoxicillin used for treating: 1, upper respiratory tract infections, such as tympanitis, nasosinusitis, pharyngitis and tonsillitis resulted from streptococcus hemolyticus, streptococcus pneumoniae, staphylococcus or haemophilus influenzae; 2, genitourinary tract infections resulted from escherichia coli,proteus mirabilis or enterococcus faecalis; 3, skin and soft tissue infection resulted from streptococcus hemolyticus, staphylococcus bacteria or escherichia coli; 4, lower respiratory tract infections, such as acute bronchitis and pneumonia, resulted from streptococcus hemolyticus, streptococcus pneumoniae, staphylococcus bacteria or haemophilus influenzae; 5, acute simple gonorrhea; and 6, typhoid, typhoid bacteria-carrier, leptospirosis and the like. The novel dosage form is characterized in that the stomach floating tablet is hydrated into gel on the surface to expand the volume thereof after contacting with the gastric juice at the body temperature because of a plurality of hydrophilic macromolecular materials contained. Meanwhile, the weight of the tablet is less than the buoyant force of the gastric juice to float the tablet on the gastric juice and prolong the retention time in the stomach.

The present invention relates to a reliable method of prediction of lower respiratory tract infection or inflammation in humans, wherein the level of pancreatic stone protein / regenerating protein (PSP / reg) is determined in serum, and a high level is indicative of the development and the severity of the disease, allowing the classification of patients according to risk.

An extract of mysore thorn powder and its medical preparation in the form of capsule or tablet with antiviral and antibacterial actions for treating upper and lower respiratory tract infections are disclosed. Its advantage is high curative effect.

The invention discloses a composition with a function of clearing heat from throats, a method for preparing the composition and application thereof. The composition comprises, by weight, 5-10 parts of whole aloe vera freeze-dried powder, 2-5 parts of phyllanthus emblica powder, 3-6 parts of radix platycodonis extract, 3-6 parts of bulbus fritillariae cirrhosae extract, 2-5 parts of fructus momordicae extract and 2-5 parts of semen sterculiae lychnophorae extract. The composition, the method and the application have the advantages that the composition has the function of clearing the heat from the throats, and symptoms such as halitosis, dysphoria and dry feces due to throat and oral inflammation can be particularly relieved while the composition intervenes with acute and chronic pharyngitis, stomatitis and oral ulcer; lower respiratory tract infection due to the throat and oral inflammation can be prevented by the aid of the composition; throat and oral mucosa rehabilitation can be promoted, and the attack frequencies of chronic inflammation or ulcer can be reduced; the composition can be used for preparing healthcare foods and medicines for preventing and treating the acute and chronic pharyngitis, the stomatitis and the oral ulcer.

The invention discloses a Tibetan medicine composition, a preparation method and an application thereof, wherein the Tibetan medicine composition includes following medicine raw materials, by weight: 10-40 parts of saffron crocus, 10-30 parts of sandalwood, 10-30 parts of tabasheer, 5-20 parts of cloves, 15-50 parts of rhizome gentiana scabra and 8-25 parts of radix glycyrrhizae. The Tibetan medicine composition is prepared through a conventional method in the field. The Tibetan medicine composition is used for preparing a medicine for treating respiratory tract diseases caused by virus infection or co-infection of virus and bacteria. The Tibetan medicine composition can be used for treating the respiratory tract diseases caused by virus infection, and especially is suitable for lower respiratory infection diseases caused by virus, is excellent in treatment effect on the diseases such as pharyngitis, laryngitis, pneumonia, bronchitis throat ache or stomatitis or the like, and especially can achieve a better treatment effect when being prepared into granules.

The invention discloses a preparation method and pharmaceutical uses of a curcumin and pidotimod composition. The curcumin and pidotimod composition is used for treating: (1) recurrent upper and lower respiratory tract infections (pharyngitis, tracheitis, bronchitis and tonsillitis); (2) ENT recurrent infections (rhinitis, sinusitis and otitis); (3) urinary system infection; (4) gynecological infection; (5) clinical patients with low cellular immune function after chemotherapy; and (6) specific and non-specific immune deficiency diseases such as cancer and the like. The curcumin and pidotimod composition can be used for reducing the number of acute attack, shortening the course of medication and reducing the degree of attack, and also can be used for the adjuvant treatment of antibiotics during acute infection. The pidotimod and curcumin composition together with various pharmaceutically acceptable excipients are comprised, and various pharmaceutically acceptable dosage forms can be prepared, including but not limited to tablets, capsules, injection agents and the like.

The invention discloses a traditional Chinese medicine composition for treating viral lower respiratory tract infection, belonging to the field of a traditional Chinese preparation. The traditional Chinese medicine composition contains herba ajugae dry paste, giant knotweed dry paste, rhodiola root dry paste and auxiliary materials, or contains herba ajugae dry paste, giant knotweed dry paste, rhodiola root dry paste, auxiliary materials and pig bile powder. The traditional Chinese medicine composition disclosed by the invention is mainly applied in traditional Chinese medicine wind-warm and lung-heat disease caused by heat toxin accumulation in the lung, and is capable of clearing away heat and toxins and protecting the lung. In the modern medicine, the viral lower respiratory tract infection belongs to the range of the wind-warm and lung-heat disease, thus the viral lower respiratory tract infection can be treated by the pharmaceutical composition disclosed by the invention.

The invention relates to a traditional Chinese medicine for treating viral lower respiratory tract infection and a preparation method thereof. The traditional Chinese medicine for treating viral lower respiratory tract infection is prepared from the following raw materials in part by weight: 3 to 6 parts of fried ephedra herb, 5 to 12 parts of gypsum, 5 to 12 parts of baical skullcap root, 5 to 12 parts of giant knotweed rhizome, 4 to 9 parts of great burdock achene, 3 to 6 parts of arisaema cum bile, 4 to 9 parts of rhizoma pinelliae preparatum and 4 to 9 parts of tangerine peel; The preparation method of the traditional Chinese medicine for treating viral lower respiratory tract infection comprises: 1) weighing the raw materials according to a mixing ratio; 2) adding water into the tangerine peel and distilling the tangerine peel to extract volatile oil; 3) filtering aqueous solution obtained after distillation, collecting filtrate, decocting medicinal slag, the fried ephedra herb, the gypsum, the baical skullcap root, the giant knotweed rhizome, the great burdock achene and the arisaema cum bile in water, filtering and obtaining filtrate; 4) mixing the filtrate and the aqueous solution, concentrating under reduced pressured, cooling, and adding ethanol; 5) filtering, recovering ethanol, concentrating under reduced pressure, drying under vacuum and obtaining dry paste; and 6) grinding the dry paste into fine powder, adding dextrin, preparing particles, drying, sieving, spraying volatile oil, uniformly mixing and bagging.

The invention belongs to the field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating the lower respiratory tract infections of infants. The preparation is characterized by being prepared from the following raw materials in parts by weight: 4-8 parts of Thunberg fritillaria bulb, 10-18 parts of snakegourd fruit, 6-12 parts of lepidium seeds, 6-10 parts of cortex mori radicis, 6-10 parts of cortex lycii radicis, 5-8 parts of balloon flower, 3-8 parts of earthworm, 3-8 parts of arisaema cum bile, 4-8 parts of bitter almond, 6-10 parts of honey-fried loquat leaf, 6-10 parts of radix scrophulariae and 3-8 parts of licorice. The Thunberg fritillaria bulb and the snakegourd fruit capable of removing heat, reducing phlegm and relieving cough and asthma are used as monarch drugs, the lepidium seeds and the cortex mori radicis capable of removing heat from lung, relieving asthma and inducing diuresis to alleviate edema are used as ministerial drugs, the cortex lycii radicis, the earthworm, the arisaema cum bile, the bitter almond, the honey-fried loquat leaf and the radix scrophulariae capable of removing heat, reducing phlegm, relieving cough and asthma and relieving convulsion for defecation are used as adjuvant drugs, the balloon flower and the licorice are conductant drugs and are also adjuvant drugs, and all the drugs jointly take the effects of clearing and descending metalic pneuma so as to relieve asthma. The invention has the efficacies of removing heat, reducing phlegm and relieving cough and asthma and has the advantages of accurate and rapid curative effect, high cure rate and the like in treating the lower respiratory tract infections of infants and convenient for taking.

The invention relates to a supersmooth antibacterial laryngeal mask. The supersmooth antibacterial laryngeal mask comprises a laryngeal mask inflation tube, wherein an inflation tube connector is connected to one end of the laryngeal mask inflation tube; an airbag is arranged at the other end of the laryngeal mask inflation tube; a bag cavity of the airbag is connected with an airbag inflation tube; an airbag inflation valve is connected to the other end of the airbag inflation tube; the surface of the airbag is coated with a supersmooth antibacterial coating; one end, close to the airbag, of the airbag inflation tube, is fixed on the laryngeal mask inflation tube. Therefore, the supersmooth antibacterial laryngeal mask disclosed by the invention has the advantages of reasonable structure, small compression and damage to a tracheal epithelium, and low respiratory tract infection rate.

The invention discloses a Shuangjinlian pharmaceutical composition and Shuangjinlian atomization inhalation solution as well as preparation methods and application of the Shuangjinlian pharmaceutical composition and the Shuangjinlian atomization inhalation solution. The Shuangjinlian pharmaceutical composition is characterized by comprising effective component extracts of 41 to 45 parts of flos lonicerae, 5 to 9 parts of trollius chinensis, 26 to 55 parts of radix scutellariae, 5 to 19 parts of forsythia and 5 to 14 parts of bupleurum in parts by weight. Compared with the honeysuckle, the flos lonicerae used in the raw materials of the invention has an obviously prominent synergistic effect with other medicinal materials in the formula, and the prepared product has an unexpected technical effect in the treatment of upper and lower respiratory tract infection and pneumonia; compared with the conventional Shuangjinlian mixture, the atomization inhalation solution can use a special atomization inhalant dosing device to enter into lungs through respiratory tracts, thereby being small in stimulation for the respiratory tracts, easy in storage, convenient to apply, good in patient compliance, and more ideal in treatment effects.

The invention discloses a Tibetan medicine composition, a preparation method and application thereof. The Tibetan medicine composition includes the following medicinal raw materials in parts by weight: 10-40 parts of saffron, 10-30 parts of sandalwood, 10-30 parts of geranium, 5-20 parts of clove, 15-50 parts of gentian flower and licorice 8‑25 servings. The preparation method is a conventional preparation method in the art. The Tibetan medicine composition is used in the preparation of medicines for treating respiratory diseases caused by viral infections, or viruses combined with bacterial infections. The Tibetan medicine composition of the present invention can treat respiratory tract diseases caused by virus infection, and is especially suitable for diseases of lower respiratory tract infection caused by viruses; for treating diseases such as pharyngitis, laryngitis, pneumonia, bronchitis, sore throat or stomatitis, the therapeutic effect is good , especially when prepared into granules, better therapeutic effect can be obtained.

The invention discloses a Shuangjinlian pharmaceutical composition and Shuangjinlian atomization inhalation solution as well as preparation methods and application of the Shuangjinlian pharmaceutical composition and the Shuangjinlian atomization inhalation solution. The Shuangjinlian pharmaceutical composition is characterized by comprising effective component extracts of 41 to 45 parts of flos lonicerae, 5 to 9 parts of trollius chinensis, 26 to 55 parts of radix scutellariae, 5 to 19 parts of forsythia and 5 to 14 parts of bupleurum in parts by weight. Compared with the honeysuckle, the flos lonicerae used in the raw materials of the invention has an obviously prominent synergistic effect with other medicinal materials in the formula, and the prepared product has an unexpected technical effect in the treatment of upper and lower respiratory tract infection and pneumonia; compared with the conventional Shuangjinlian mixture, the atomization inhalation solution can use a special atomization inhalant dosing device to enter into lungs through respiratory tracts, thereby being small in stimulation for the respiratory tracts, easy in storage, convenient to apply, good in patient compliance, and more ideal in treatment effects.